BACKGROUND: Previously, we have shown the ability of the bacteriophage T4 and its substrain HAP1 (selected for a higher affinity to melanoma cells) to reveal antimetastatic activity in a mouse melanoma model. Here, we investigated the potential phage anticancer activity in primary tumour models. MATERIALS AND METHODS: Mice were inoculated subcutaneously with B16 or LLC cells (collected from in vitro culture). Bacteriophages T4 and HAP1 were injected intraperitoneally daily (8 x 10(8)pfu/mouse, except the experiment concerning the dose-dependence). RESULTS: Treatment with purified preparations of bacteriophage T4 resulted in significant reduction of tumour size, the effect being dose-dependent. HAP1 was more effective than T4 and its activity was also dose-dependent. Parallel experiments with non-purified bacteriophage lysates resulted in significant stimulation of tumour growth. CONCLUSION: These data suggest that purified bacteriophages may inhibit tumour growth, a phenomenon with potentially important clinical implications in oncology.
BACKGROUND: Previously, we have shown the ability of the bacteriophage T4 and its substrain HAP1 (selected for a higher affinity to melanoma cells) to reveal antimetastatic activity in a mousemelanoma model. Here, we investigated the potential phage anticancer activity in primary tumour models. MATERIALS AND METHODS:Mice were inoculated subcutaneously with B16 or LLC cells (collected from in vitro culture). Bacteriophages T4 and HAP1 were injected intraperitoneally daily (8 x 10(8)pfu/mouse, except the experiment concerning the dose-dependence). RESULTS: Treatment with purified preparations of bacteriophage T4 resulted in significant reduction of tumour size, the effect being dose-dependent. HAP1 was more effective than T4 and its activity was also dose-dependent. Parallel experiments with non-purified bacteriophage lysates resulted in significant stimulation of tumour growth. CONCLUSION: These data suggest that purified bacteriophages may inhibit tumour growth, a phenomenon with potentially important clinical implications in oncology.
Authors: Michał Zimecki; Jolanta Artym; Maja Kocieba; Beata Weber-Dabrowska; Jan Borysowski; Andrzej Górski Journal: Med Microbiol Immunol Date: 2009-12-02 Impact factor: 3.402
Authors: Karin L Lee; Abner A Murray; Duc H T Le; Mee Rie Sheen; Sourabh Shukla; Ulrich Commandeur; Steven Fiering; Nicole F Steinmetz Journal: Nano Lett Date: 2017-06-26 Impact factor: 11.189
Authors: Md Zeyaullah; Mohan Patro; Irfan Ahmad; Kawthar Ibraheem; P Sultan; M Nehal; Arif Ali Journal: Pathol Oncol Res Date: 2012-06-20 Impact factor: 2.874
Authors: A Górski; E Jończyk-Matysiak; M Łusiak-Szelachowska; B Weber-Dąbrowska; R Międzybrodzki; J Borysowski Journal: Clin Exp Immunol Date: 2018-01-23 Impact factor: 4.330